The currently established nomenclature for psychotropic drugs is outdated and no longer reflects the progress of neuroscience. In response to this situation, the Neurosci-ence-based Nomenclature (NbN) was developed: A system for the classification of psy-chotropic drugs, which brings important advantages for patients, clinicians, and re-searchers. The German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN) supports the introduction of the NbN in care, science, and teaching.